Celerion
, a provider of early stage clinical research solutions, announces the launch of a new Hybrid Phase I/ ECG Core lab. The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion’s global Phase I clinical network. Celerion’s approach employs new technology to perform automated measurement of ECG recordings, thereby minimizing cardiologist review and providing clients with faster access to data. The system also identifies the small number of ECG recordings that will still require cardiologist review. This reduction in cardiologist involvement, combined with smaller overhead compared to traditional ECG Core labs supporting global clinical trials, allows Celerion to offer cost and time savings to clients.
The Hybrid Phase I/ ECG Core lab was developed in collaboration with
AMPS-LLC
(Analyzing Medical Parameters for Solutions), and Global Instrumentation, LLC (GI). AMPS-LLC is a world leader in high quality ECG analysis software utilized by many ECG Core labs. Celerion is proud to host one of the first installations of AMPS’ FAT-QT and TrialPerfect software platforms, in addition to being one of the first contract research organization (CRO) to deploy the Global Instrumentation technology for Phase I/ ECG trials.
“By integrating the ECG functions within our clinic network, minimizing traditional ECG overhead and providing more automation, Celerion enables fast access to data and cost-effective solutions that deliver high-quality data for the execution of thorough QT studies and ECG assessment in SAD and MAD programs,” said Susan Thornton, CEO of Celerion.
According to Jim DeMaso, President of Global Instrumentation, “The GI M12R recorder and M12A Enterprise software provide Holter functions with full standard 12-lead ECG functionality in a centralized data management system designed for the requirements of clinical trials. We are pleased to be part of the Celerion/AMPS collaboration.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.